Protein / target
Angiopoietin-2
Protein at a glance
Biological role
Receptor tyrosine kinase binding
Primary system
Cardiovascular system
Strongest disease association
lymphatic malformation 10
Therapeutic maturity
Clinically validated target
Druggability
Antibody
Clinical development
1 approved · 7 in clinical development
Research activity
Emerging research
Derived from structured UniProt, Open Targets and literature data on this page.
Protein profile
Canonical identity and biological annotation from UniProt.
Function
Binds to TEK/TIE2, competing for the ANGPT1 binding site, and modulating ANGPT1 signaling (PubMed:15284220, PubMed:19116766, PubMed:19223473, PubMed:9204896). Can induce tyrosine phosphorylation of TEK/TIE2 in the absence of ANGPT1 (PubMed:15284220, PubMed:19116766, PubMed:19223473, PubMed:9204896). In the absence of angiogenic inducers, such as VEGF, ANGPT2-mediated loosening of cell-matrix contacts may induce endothelial cell apoptosis with consequent vascular regression. In concert with VEGF, it may facilitate endothelial cell migration and proliferation, thus serving as a permissive angiogenic signal (PubMed:15284220, PubMed:19116766, PubMed:19223473, PubMed:9204896). Involved in the regulation of lymphangiogenesis (PubMed:32908006)
Subcellular location
Domains and Gene Ontology detail (27)Hide
Domains & features
Gene Ontology
- Ccell projection
- Cextracellular matrix
- Cextracellular region
- Cextracellular space
- Fmetal ion binding
- Freceptor ligand activity
- Freceptor tyrosine kinase binding
- Fsignaling receptor binding
- Pangiogenesis
- Panimal organ regeneration
- Pblood coagulation
- Pcellular response to growth factor stimulus
Biological roles
What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.
View supporting evidenceHide supporting evidence
Kinase signalling
- ·Binds to TEK/TIE2, competing for the ANGPT1 binding site, and modulating ANGPT1 signalin…
Cell adhesion
- ·extracellular matrix
Transcriptional regulation
- ·gene expression
Haemostasis
- ·blood coagulation
View underlying pathways (1)Hide underlying pathways
Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.
Interaction neighbourhood
Proteins with the strongest functional or physical association. Node size and line weight reflect STRING confidence; hover or select a partner to inspect one association.
Functional and physical associations from STRING v12.0. Only associations with this protein are drawn — partner-to-partner links are not part of this evidence.
Drugs targeting this protein
Whether each drug engages this protein directly or through a complex, and how many other targets are recorded for it. Direct binders with few recorded targets are listed first.
Angiopoietin-2 inhibitor
Appears in clinical studies involving diabetic macular edema, wet macular degeneration, macular retinal edema, wet macular degeneration
ChEMBL mechanism, action type and target identity. Open Targets clinical status and indications.
Translational evidence
Why this target matters therapeutically — disease associations, drugs in development, tractability and safety, from Open Targets.
Strongest genetic associations
Human genetic evidence — the most direct causal link between this target and a disease.
Highest-confidence therapeutic associations
Diseases where a drug acting on this target has already reached clinical development.
Highest overall evidence
Remaining associations by Open Targets' aggregated evidence score.
Show all associationsHide all associations
Open Targets ranks 1,013 associations for this target and we store the top 10 by aggregated score. The long tail is largely literature co-mention and RNA-expression evidence, not evidence that this target drives those diseases.
Known drugs · 8 total
diabetic macular edema · age-related macular degeneration · age-related macular degeneration
breast cancer · neuropathic pain · ovarian cancer
ovarian cancer · melanoma
renal cell carcinoma · glioblastoma
COVID-19 · pneumonia · COVID-19
diabetic macular edema · wet macular degeneration · macular retinal edema
colorectal cancer · metastatic colorectal cancer · hepatocellular carcinoma
Tractability
Clinical trials
Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein.
Show remaining trials (24)Hide
ClinicalTrials.gov via the drug-target graph.
Research activity
Papers linked directly to this protein. This is the protein's own literature — descriptor-derived papers are kept separate below.
Most cited
Recent
Europe PMC papers linked directly to this protein.
Forefront confidence
Our own weighting of the evidence behind each disease association. Human genetics and clinical evidence count for most; literature co-mention counts for little, because two entities sharing an abstract is not evidence that one drives the other.
This ranking differs from Open Targets' own: re-weighting moves genetically-evidenced diseases above more heavily co-mentioned ones. The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the underlying per-type scores are shown above so the calculation can be checked.
What's happening now
Recent activity around this target, drawn from one canonical event stream. Every item is reached through a drug that targets this protein, so each event is news about that drug rather than about the protein directly.
- Clinical trial activityOllin hauls in $330M to enlist Vabysmo challenger in phase 3 eye disease gauntlet
- New publicationAqueous Humor Biomarkers, Efficacy, and Safety in Patients with Naïve Diabetic Macular Edema Treated with Faricimab: The ALTIMETER Study.
- New publicationFour-Year Outcomes of Faricimab in Diabetic Macular Edema: Results from the RHONE-X Extension Trial.
- Regulatory approval
Approval: Vabysmo (EMA)
- New publicationEfficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials.
Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.